From probes into marketing practices, to a dearth of new drugs, to cheap reimportation, big drugmakers have had a stormy 2003, but analysts see a brightening landscape -- call it partly cloudy -- in 2004.
From probes into marketing practices, to a dearth of new drugs, to cheap reimportation, big drugmakers have had a stormy 2003, but analysts see a brightening landscape -- call it partly cloudy -- in 2004.